Literature DB >> 25909683

Evaluation of vaccine seroresponse rates and adverse event rates through Bayesian and frequentist methods.

Jin Liu1, Feng Chen, Feng-Cai Zhu, Jian-Ling Bai, Jing-Xin Li, Hao Yu, Pei Liu, Ping Zeng.   

Abstract

In the evaluation of vaccine seroresponse rates and adverse reaction rates, extreme test results often occur, with substantial adverse event rates of 0% and/or seroresponse rates of 100%, which has produced several data challenges. Few studies have used both the Bayesian and frequentist methods on the same sets of data that contain extreme test cases to evaluate vaccine safety and immunogenicity. In this study, Bayesian methods were introduced, and the comparison with frequentist methods was made based on practical cases from randomized controlled vaccine trials and a simulation experiment to examine the rationality of the Bayesian methods. The results demonstrated that the Bayesian non-informative method obtained lower limits (for extreme cases of 100%) and upper limits (for extreme cases of zero), which were similar to the limits that were identified with the frequentist method. The frequentist rate estimates and corresponding confidence intervals (CIs) for extreme cases of 0 or 100% always equaled and included 0 or 100%, respectively, whereas the Bayesian estimations varied depending on the sample size, with none equaling zero or 100%. The Bayesian method obtained more reasonable interval estimates of the rates with extreme data compared with the frequentist method, whereas the frequentist method objectively expressed the outcomes of clinical vaccine trials. The two types of statistical results are complementary, and it is proposed that the Bayesian and frequentist methods should be combined to more comprehensively evaluate clinical vaccine trials.

Keywords:  BCIs, Bayesian credible intervals; Bayesian method; C, control group; CIs, confidence intervals; CLl, lower confidence limit; CLu, upper confidence limit; FDA/CBER, Food and Drug Administration/ Center for Biologics Evaluation and Research; HAV, hepatitis A virus; HPV 16/18 AS04-adjuvanted, human papillomavirus vaccine -16/18 AS04-adjuvanted vaccine; HPV 6/11/16/18, human papillomavirus 6/11/16/18 quadrivalent vaccine; Hib conjugate, haemophilus influenza type b conjugate vaccine; MMRV, measles, mumps, rubella and varicella vaccine; T, test group; adverse event rates; extreme data; frequentist method; seroresponse rates; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25909683      PMCID: PMC4514417          DOI: 10.1080/21645515.2015.1008932

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

1.  Confidence interval construction for proportion difference in small-sample paired studies.

Authors:  Man-Lai Tang; Nian-Sheng Tang; Ivan S F Chan
Journal:  Stat Med       Date:  2005-12-15       Impact factor: 2.373

2.  Small proportions: what to report for confidence intervals?

Authors:  Hilde Tobi; Paul B van den Berg; Lolkje T W de Jong-van den Berg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-04       Impact factor: 2.890

3.  Constructing binomial confidence intervals with near nominal coverage by adding a single imaginary failure or success.

Authors:  Craig B Borkowf
Journal:  Stat Med       Date:  2006-11-15       Impact factor: 2.373

4.  Improved exact confidence intervals for the odds ratio in two independent binomial samples.

Authors:  Che-Yang Lin; Ming-Chung Yang
Journal:  Biom J       Date:  2006-12       Impact factor: 2.207

5.  Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers.

Authors:  H Laurichesse; F Gourdon; H L Smits; T H Abdoe; J M Estavoyer; H Rebika; P Pouliquen; P Catalina; C Dubray; J Beytout
Journal:  Clin Microbiol Infect       Date:  2007-04       Impact factor: 8.067

6.  Interval estimation of binomial proportion in clinical trials with a two-stage design.

Authors:  Wei-Yann Tsai; Yunchan Chi; Chia-Min Chen
Journal:  Stat Med       Date:  2008-01-15       Impact factor: 2.373

7.  Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.

Authors:  Duminda N Wijeysundera; Peter C Austin; Janet E Hux; W Scott Beattie; Andreas Laupacis
Journal:  J Clin Epidemiol       Date:  2008-10-23       Impact factor: 6.437

8.  Confidence intervals for a ratio of two independent binomial proportions.

Authors:  Robert M Price; Douglas G Bonett
Journal:  Stat Med       Date:  2008-11-20       Impact factor: 2.373

9.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

10.  Improving interval estimation of binomial proportions.

Authors:  X H Zhou; C M Li; Z Yang
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2008-07-13       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.